Nanobiotix S.A.
NBTX
Cena:
$ 41.01
+0.83 (2.07%)
Valuace
93
Růst
41
Zdraví
43
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
VOTING RIGHTS AND SHARES CAPITAL OF THE COMPANY
13-01-2026
IN ACCORDANCE WITH ARTICLES L.233-8 II OF THE FRENCH COMMERCIAL CODE AND 223-16 OF THE GENERAL REGUL...
Více zde
VOTING RIGHTS AND SHARES CAPITAL OF THE COMPANY
17-12-2025
IN ACCORDANCE WITH ARTICLES L.233-8 II OF THE FRENCH COMMERCIAL CODE AND 223-16 OF THE GENERAL REGU...
Více zde
NANOBIOTIX TO JOIN CAC MID 60 AND SBF 120 INDICES ON EURONEXT PARIS
15-12-2025
PARIS AND CAMBRIDGE, MASS., DEC. 15, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO –– NA...
Více zde
NANOBIOTIX PROVIDES THIRD QUARTER 2025 OPERATIONAL AND FINANCIAL UPDATE ALONG WITH 2026 CLINICAL OUTLOOK
24-11-2025
PARIS AND CAMBRIDGE, MASS., NOV. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO –– NA...
Více zde
NANOBIOTIX ANNOUNCES CURADIGM NANOPRIMER PLATFORM ADVANCEMENTS WITH UPDATED PLANS FOR INTERNAL PIPELINE DEVELOPMENT AND EXTERNAL COLLABORATIONS
13-11-2025
PARIS AND CAMBRIDGE, MASS., NOV. 13, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO –– NASD...
Více zde
NANOBIOTIX TO PARTICIPATE IN INVESTOR CONFERENCES THE WEEK OF NOVEMBER 10TH
03-11-2025
PARIS AND CAMBRIDGE, MASS., NOV. 03, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO - NASDAQ: N...
Více zde
NANOBIOTIX ANNOUNCES STRATEGIC ROYALTY MONETIZATION AGREEMENT WITH HEALTHCARE ROYALTY FOR UP TO $71 MILLION AND EXTENDS CASH RUNWAY TOWARD LONG-TERM GROWTH
31-10-2025
PARIS AND CAMBRIDGE, MASS., OCT. 31, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO –– NASD...
Více zde
NANOBIOTIX ANNOUNCES FIRST DATA FROM PHASE 1 STUDY EVALUATING JNJ-1900 (NBTXR3) FOR PATIENTS WITH ESOPHAGEAL CANCER
01-10-2025
DATA PRESENTED AT THE 2025 ANNUAL MEETING OF THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO) ON ...
Více zde
NANOBIOTIX PROVIDES BUSINESS UPDATE AND REPORTS HALF YEAR 2025 FINANCIAL RESULTS
30-09-2025
PARIS AND CAMBRIDGE, MASS., SEPT. 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO - NASDAQ: ...
Více zde
NANOBIOTIX ANNOUNCES UPDATED PHASE 1 RESULTS CONTINUING TO SUPPORT JNJ-1900 (NBTXR3) PLUS ANTI-PD-1 AS A POTENTIAL NEW 1L OR 2L+ OPTION IN ANTI-PD-1 NAÏVE OR RESISTANT R/M-HNSCC
29-09-2025
DATA PRESENTED AS A “TOP-RATED ABSTRACT IN HEAD AND NECK CANCER” AT THE 2025 ANNUAL MEETING OF T...
Více zde
NANOBIOTIX ANNOUNCES NEW RESULTS FROM A PHASE 1 STUDY EVALUATING JNJ-1900 (NBTXR3) IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS AS A 2L+ THERAPY FOR PATIENTS WITH PRIMARY CUTANEOUS MELANOMA RESISTANT TO ANTI-PD-1
17-09-2025
DATA SHOW A FAVORABLE SAFETY PROFILE AND EARLY EFFICACY SIGNALS IN A HEAVILY PRE-TREATED POPULATION ...
Více zde
NANOBIOTIX TO PARTICIPATE IN THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE
02-09-2025
PARIS AND CAMBRIDGE, MASS., SEPT. 02, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO –– NAS...
Více zde
NANOBIOTIX ANNOUNCES REGULATORY HARMONIZATION AND NEW COMPOSITION OF MATTER PATENT FILED FOR JNJ-1900 (NBTXR3)
07-07-2025
PARIS AND CAMBRIDGE, MASS., JULY 07, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO –– NASD...
Více zde
NANOBIOTIX TO PARTICIPATE IN THE JEFFERIES GLOBAL HEALTHCARE INVESTOR CONFERENCE
28-05-2025
PARIS AND CAMBRIDGE, MASS., MAY 28, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO –– NASDA...
Více zde
NANOBIOTIX PROVIDES FIRST QUARTER 2025 OPERATIONAL AND FINANCIAL UPDATE
21-05-2025
PARIS AND CAMBRIDGE, MASS., MAY 21, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO - NASDAQ: NB...
Více zde
NANOBIOTIX TO PARTICIPATE IN THE H.C. WAINWRIGHT 3RD ANNUAL BIOCONNECT INVESTOR CONFERENCE AT NASDAQ
12-05-2025
PARIS AND CAMBRIDGE, MASS., MAY 12, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO –– NASDA...
Více zde
NANOBIOTIX ANNOUNCES FULL RESULTS FROM COMPLETED PHASE 1 STUDY EVALUATING JNJ-1900 (NBTXR3) IN PANCREATIC CANCER
05-05-2025
RESULTS DEMONSTRATED FAVORABLE SAFETY, INJECTION FEASIBILITY, AND ENCOURAGING ONCOLOGIC OUTCOMES IN ...
Více zde
NANOBIOTIX ANNOUNCES PRESENTATION OF FULL RESULTS FROM COMPLETED PHASE 1 STUDY EVALUATING JNJ-1900 (NBTXR3) IN PANCREATIC CANCER FOLLOWED BY A CONFERENCE CALL
30-04-2025
PARIS AND CAMBRIDGE, MASS., APRIL 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO –– NA...
Více zde
NANOBIOTIX PROVIDES BUSINESS UPDATE AND REPORTS FULL YEAR 2024 FINANCIAL RESULTS
02-04-2025
GLOBAL DEVELOPMENT PROGRAM FOR JNJ-1900 (NBTXR3) PROCEEDING AS PLANNED, WITH OPPORTUNITY TO ADDRESS ...
Více zde
NANOBIOTIX TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2024 OPERATIONAL AND FINANCIAL UPDATE ON APRIL 2, 2025
31-03-2025
CONFERENCE CALL AND WEBCAST SCHEDULED FOR THURSDAY, APRIL 3, 2025, AT 8:00 AM EDT / 2:00 PM CEST CON...
Více zde
NANOBIOTIX ANNOUNCES FIRST DATA FROM THE COMPLETED DOSE ESCALATION PART OF A PHASE 1 STUDY EVALUATING NBTXR3 (JNJ-1900) AS A 2L+ THERAPY FOR PATIENTS WITH LOCALLY ADVANCED NSCLC
27-03-2025
PARIS AND CAMBRIDGE, MASS., MARCH 27, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO –– NAS...
Více zde
NANOBIOTIX ANNOUNCES PRESENTATION OF DATA FROM TWO PHASE 1 STUDIES EVALUATING JNJ-1900 (NBTXR3) AT THE EUROPEAN LUNG CANCER CONFERENCE
20-03-2025
PARIS AND CAMBRIDGE, MASS., MARCH 20, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO –– NAS...
Více zde
NANOBIOTIX STRENGTHENS FINANCIAL POSITION THROUGH AMENDMENT OF GLOBAL LICENSING AGREEMENT FOR JNJ-1900 (NBTXR3) AND EXTENDS CASH VISIBILITY TO MID-2026
17-03-2025
CONFERENCE CALL AND WEBCAST SCHEDULED FOR MARCH 18, 2025, AT 8:30 A.M. EDT / 1:30 P.M. CET CONFERENC...
Více zde
NANOBIOTIX TO PARTICIPATE IN MULTIPLE INVESTOR CONFERENCES IN FEBRUARY AND MARCH 2025
29-01-2025
PARIS AND CAMBRIDGE, MASS., JAN. 29, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO –– NASD...
Více zde
NANOBIOTIX ANNOUNCES FIRST PATIENT DOSED IN A NEW RANDOMIZED PHASE 2 STUDY EVALUATING JNJ-1900 (NBTXR3) FOR PATIENTS WITH STAGE 3 UNRESECTABLE NON-SMALL CELL LUNG CANCER
21-01-2025
PARIS AND CAMBRIDGE, MASS., JAN. 21, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO –– NASD...
Více zde
NANOBIOTIX TO INTRODUCE VISION FOR TRANSFORMING DRUG DESIGN AND DEVELOPMENT WITH NEXT NANOTHERAPEUTIC PLATFORM ON 19 DECEMBER 2024
17-12-2024
PARIS AND CAMBRIDGE, MASS., DEC. 17, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO –– NASD...
Více zde
NANOBIOTIX ANNOUNCES COMPLETION OF PHASE 1 STUDY OF NBTXR3 (JNJ-1900) IN PANCREATIC CANCER
09-12-2024
PARIS AND CAMBRIDGE, MASS., DEC. 09, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO –– NASD...
Více zde
NANOBIOTIX PROVIDES THIRD QUARTER 2024 UPDATE AND PROGRESS ON NANOTHERAPEUTICS PLATFORMS
12-11-2024
PARIS AND CAMBRIDGE, MASS., NOV. 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO - NASDAQ: N...
Více zde
NANOBIOTIX TO PARTICIPATE IN MULTIPLE INVESTOR CONFERENCES IN NOVEMBER
31-10-2024
~ GUGGENHEIM'S INAUGURAL HEALTHCARE INNOVATION CONFERENCE, NOV 11-13 ~ ~ STIFEL HEALTHCARE CONFEREN...
Více zde
NANOBIOTIX PROVIDES BUSINESS UPDATE AND REPORTS HALF YEAR 2024 FINANCIAL RESULTS
18-09-2024
PARIS AND CAMBRIDGE, MASS., SEPT. 18, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO - NASDAQ: ...
Více zde
Dokumenty nejsou k dispozici
